Cellectis, which is developing cancer immunotherapies based on gene-edited CAR T-cells, filed on Friday with the SEC to raise up to $115 million in an initial public offering. The company currently trades on the Alternext market of the Euronext Paris under the symbol ALCLS.
Recent cancer immunotherapy biotech IPOs include Juno Therapeutics (JUNO; +87%), Kite Pharma (KITE; +276%) and Bellicum Pharmaceuticals (BLCM; +18%).
The company is backed by both Pfizer (NYSE: PFE) and the French government.
The Paris, France-based company, which was founded in 2000 and has $28 million in cash as of June 30, 2014, plans to list on the NASDAQ under the symbol CLLS. Cellectis initially filed confidentially on December 19, 2014. BofA Merrill Lynch, Jefferies, Piper Jaffray and Oppenheimer are the joint bookrunners on the deal. No pricing terms were disclosed.
